Indefinite Delivery Contract SPE2DU25D9526

The federal contract IDV award SPE2DU25D9526 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.

The original solicitation, expected to be issued in March 2024, will establish Pharmaceutical Prime Vendor Global Program Generation V contracts for the DLA Troop Support Medical Supply Chain. The unrestricted, fully competitive acquisition aims to make multiple regional awards, with the intention of having at least three different contractors, to ensure resiliency and access to vital pharmaceuticals during contingencies or natural disasters. The contracts will have a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion. Awards will be made on a lowest price technically acceptable (LPTA) basis, with the government reserving the right to use a reverse auction to determine final distribution fees.